Camp4 Therapeutics Revenue Growth Rates (CAMP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Camp4 Therapeutics Corporation  (NASDAQ: CAMP)
 

CAMP's Revenue Growth by Quarter and Year

Camp4 Therapeutics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CAMP/growth
https://api.csimarket.com/api/v1/companies/CAMP/fundamentals
https://api.csimarket.com/api/v1/companies/CAMP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CAMP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.90
2nd Quarter June 1.78
1st Quarter March 1.29
FY 4.97

CAMPs Annual Revenue
Camp4 Therapeutics's Revenue in the fiscal year 2025 $ 3.50 millions
Camp4 Therapeutics's Revenue in the fiscal year 2024 $ 0.65 millions
Camp4 Therapeutics's Revenue in the fiscal year 2023 $ 294.95 millions
Camp4 Therapeutics's Revenue in the fiscal year 2022 $ 295.84 millions
Camp4 Therapeutics's Revenue in the fiscal year 2021 $ 308.59 millions




CAMP Revenue third quarter 2026 Y/Y Growth Comment
Camp4 Therapeutics Corporation achieved in the third quarter 2026, above Company average Revenue surge of 137.37% year on year, to $ 1.90 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Revenue growth. While Camp4 Therapeutics Corporation' s Revenue doubling of 137.37% ranks overall at the positon no. 1117 in the third quarter 2026.


CAMP Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 137.37 %
2nd Quarter June 18.67 %
1st Quarter March 50 %
FY   -

Financial Statements
Camp4 Therapeutics's third quarter 2026 Revenue $ 1.90 millions CAMP's Income Statement
Camp4 Therapeutics's third quarter 2025 Revenue $ 0.80 millions Quarterly CAMP's Income Statement


CAMP Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.69 %
2nd Quarter June 37.98 %
1st Quarter March 268.57 %
FY (Year on Year)   -


Back to CAMP Growth rate Comparisons >> Back to CAMP Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #218
Overall #1117

Revenue Y/Y Growth Statistics
High Average Low
50.82 % -0.82 % -100 %
(Feb 28 2014)   (Nov 30 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #218
Overall #1117
Revenue Y/Y Growth Statistics
High Average Low
50.82 % -0.82 % -100 %
(Feb 28 2014)   (Nov 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Camp4 Therapeutics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
271.84 % 2.73 % -100 %
(Mar 31 2026)  


CAMP's III. Quarter Q/Q Revenue Comment
Camp4 Therapeutics Corporation achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.69%, to $ 1.90 millions, from $1.78 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Camp4 Therapeutics's Revenue growth quarter on quarter, overall rank is 298.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #298
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #298
Revenue Q/Q Growth Statistics
High Average Low
271.84 % 2.73 % -100 %
(Mar 31 2026)  


CAMP's III. Quarter Q/Q Revenue Comment
Camp4 Therapeutics Corporation achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.69%, to $ 1.90 millions, from $1.78 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Camp4 Therapeutics's Revenue growth quarter on quarter, overall rank is 298.


Camp4 Therapeutics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.22
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 7.17 %
Seq. Revenue Growth (TTM) Overall Ranking # 3143


Cumulative Revenue growth Comment
Camp4 Therapeutics saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 137.37% year on year, to $ 4 millions if the fiscal year would have ended in Jun 30 2026.
Camp4 Therapeutics's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Camp4 Therapeutics realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.17 % from $3.93 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 4.36%.

Camp4 Therapeutics Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 422
S&P 500 # 3143
Cumulative Revenue growth Comment
Camp4 Therapeutics saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 137.37% year on year, to $ 4 millions if the fiscal year would have ended in Jun 30 2026.
Camp4 Therapeutics's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Camp4 Therapeutics realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Mar 31 2026 rise was beneth at 7.17 % from $3.93 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 4.36%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.17 % increase from $3.93 millions in the period from Mar 31 2026 to Jun 30 2025.

Camp4 Therapeutics Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 422
S&P 500 # 3143




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CAMP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions


About Camp4 Therapeutics Revenue Growth Rates (CAMP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Calamp Corp (CIK 730255).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-003368
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Calamp Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.